Application of Emerging Technologies for Cancer Research (Sbir/Sttr)

The summary for the Application of Emerging Technologies for Cancer Research (Sbir/Sttr) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Application of Emerging Technologies for Cancer Research (Sbir/Sttr): This RFA will utilize the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) mechanisms, but will be run in parallel with a RFA of identical scientific scope (CA-05-003, http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-003.html) that will utilize the, NIH R21/R33 Phased Innovation Award and the R33 Exploratory/Developmental Award. The National Cancer Institute (NCI) invites applications for research projects to evaluate the usefulness of emerging technologies that are ready for initial application to clinical or biological questions in cancer research. Projects should be designed to demonstrate that the technology is robust and yields reproducible measurements. Projects should also be designed to gather preliminary data to support the use of the technology in a future project(s) with a clinical or biological focus. It is expected that some refinement or adaptation of the technology may be appropriate in the initial phase of the project, but projects requiring significant technology development effort are not appropriate. In addition, applications that propose the use of commercially available technology under standard conditions, or any technology that is already commonly accepted for the proposed use, are not appropriate. (Applicants proposing projects focused on biological or clinical questions are encouraged to contact their program director to discuss appropriate funding opportunities.) This initiative is part of a broader technology development program within the NCI. That program underscores the desire of NCI to develop and integrate novel technologies focused on the molecular analysis of cancers and their micro-environment in support of cancer research, diagnosis, and treatment. In the research continuum of discovery, development, and delivery, this program thus emphasizes the link between development and delivery. This specific initiative will serve as a tool to develop emerging technologies in an appropriate biological or clinical context. This RFA capitalizes on both the success and intent of the original NCI sponsored Innovative Molecular Analysis Technologies (IMAT) program in bringing together a multi-disciplinary group of scientists and engineers to work on cancer and the expansion of interest in technology development across the NCI and other NIH institutes. This continuation of the IMAT program consists of the following three initiatives: Innovative Technologies for the Molecular Analysis of Cancer; Innovations in Cancer Sample Preparation; and Application of Emerging Technologies for Cancer Research. This RFA is designed to replace and expand on the Applications of Innovative Technologies for the Molecular Analysis of Cancer (PAR-01-107). It will support studies that start with an unproven technology, adapt or refine the technology slightly as needed, and begin to generate biological data to assess the relative robustness of the technology in the chosen biological or clinical context. Projects requiring significant technology development may be most suitable for RFA (CA-05-006), Innovative Technologies for the Molecular Analysis of Cancer SBIR/STTR (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-006.html). Technologies developed or adapted for sample preparation methodology may be most suitable for RFA (CA-05-008), Innovations in Cancer Sample Preparation SBIR/STTR (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-05-008.html) (see MECHANISMS OF SUPPORT). Applications of in vivo imaging technologies and projects with bioinformatics or statistics as their primary focus are not included under this RFA. Researchers who emphasize the assessment of in vivo imaging technologies as the primary focus of their grant application should contact the Cancer Imaging Program (http://www.cancer.gov/cip/) for information on appropriate funding opportunities. Researchers focusing on applying new bioinformatics or statistical techniques as the primary focus of their application should consider one of the BISTI initiatives (http://www.bisti.nih.gov/bistic_funding.cfm).